Cargando…

Evaluation of Adherence to Oral Hypoglycemic Agent Prescription in Patients with Type 2 Diabetes

BACKGROUND: Diabetes is a global health problem that has affected more than 400 million people worldwide. Adherence to treatment is considered to be one of the most impor tant and deterministic factors in the treatment of diabetes. This study investigates medication adherence and factors af fecting...

Descripción completa

Detalles Bibliográficos
Autores principales: Irani, Mahtab, Yazdi, Mohammad Sarafraz, Irani, Meisam, Sistani, Sina Naghibi, Ghareh, Sahar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SBDR - Society for Biomedical Diabetes Research 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380091/
https://www.ncbi.nlm.nih.gov/pubmed/33905472
http://dx.doi.org/10.1900/RDS.2020.16.41
_version_ 1784768809748398080
author Irani, Mahtab
Yazdi, Mohammad Sarafraz
Irani, Meisam
Sistani, Sina Naghibi
Ghareh, Sahar
author_facet Irani, Mahtab
Yazdi, Mohammad Sarafraz
Irani, Meisam
Sistani, Sina Naghibi
Ghareh, Sahar
author_sort Irani, Mahtab
collection PubMed
description BACKGROUND: Diabetes is a global health problem that has affected more than 400 million people worldwide. Adherence to treatment is considered to be one of the most impor tant and deterministic factors in the treatment of diabetes. This study investigates medication adherence and factors af fecting it in patients with type 2 diabetes. METHODS: This cross-sectional study investigated 136 patients with type 2 diabetes in 2018-2019. Data collection was done using a checklist that included information on personal characteristics, medication, and healthcare. The collected data were analyzed by statistical tests in SPSS 25 software. RESULTS: 79.4% of the patients adhered to prescribed medication. Medication adherence had no significant relationship with taking other drugs, fasting blood sugar (FBS), and the daily number of hypoglycemic tablets (p ˃ 0.05). However, adherence to medication was significantly associated with age, gender, income, hemoglobin A1c, medication period, and hypoglycemia (p < 0.05). CONCLUSIONS: Higher levels of adherence were` obser ved among females aged below 60 years, with higher income, a hemoglobin A1c level below 7%, a medication period of less than 10 years, and among patients without hypoglycemia. Regarding drug type, adherence levels were lower in people taking glibenclamide.
format Online
Article
Text
id pubmed-9380091
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SBDR - Society for Biomedical Diabetes Research
record_format MEDLINE/PubMed
spelling pubmed-93800912022-08-26 Evaluation of Adherence to Oral Hypoglycemic Agent Prescription in Patients with Type 2 Diabetes Irani, Mahtab Yazdi, Mohammad Sarafraz Irani, Meisam Sistani, Sina Naghibi Ghareh, Sahar Rev Diabet Stud Original Data BACKGROUND: Diabetes is a global health problem that has affected more than 400 million people worldwide. Adherence to treatment is considered to be one of the most impor tant and deterministic factors in the treatment of diabetes. This study investigates medication adherence and factors af fecting it in patients with type 2 diabetes. METHODS: This cross-sectional study investigated 136 patients with type 2 diabetes in 2018-2019. Data collection was done using a checklist that included information on personal characteristics, medication, and healthcare. The collected data were analyzed by statistical tests in SPSS 25 software. RESULTS: 79.4% of the patients adhered to prescribed medication. Medication adherence had no significant relationship with taking other drugs, fasting blood sugar (FBS), and the daily number of hypoglycemic tablets (p ˃ 0.05). However, adherence to medication was significantly associated with age, gender, income, hemoglobin A1c, medication period, and hypoglycemia (p < 0.05). CONCLUSIONS: Higher levels of adherence were` obser ved among females aged below 60 years, with higher income, a hemoglobin A1c level below 7%, a medication period of less than 10 years, and among patients without hypoglycemia. Regarding drug type, adherence levels were lower in people taking glibenclamide. SBDR - Society for Biomedical Diabetes Research 2021-05-01 /pmc/articles/PMC9380091/ /pubmed/33905472 http://dx.doi.org/10.1900/RDS.2020.16.41 Text en Copyright © by Lab & Life Press https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 Unported (CC BY 4.0) (https://creativecommons.org/licenses/by/4.0/)
spellingShingle Original Data
Irani, Mahtab
Yazdi, Mohammad Sarafraz
Irani, Meisam
Sistani, Sina Naghibi
Ghareh, Sahar
Evaluation of Adherence to Oral Hypoglycemic Agent Prescription in Patients with Type 2 Diabetes
title Evaluation of Adherence to Oral Hypoglycemic Agent Prescription in Patients with Type 2 Diabetes
title_full Evaluation of Adherence to Oral Hypoglycemic Agent Prescription in Patients with Type 2 Diabetes
title_fullStr Evaluation of Adherence to Oral Hypoglycemic Agent Prescription in Patients with Type 2 Diabetes
title_full_unstemmed Evaluation of Adherence to Oral Hypoglycemic Agent Prescription in Patients with Type 2 Diabetes
title_short Evaluation of Adherence to Oral Hypoglycemic Agent Prescription in Patients with Type 2 Diabetes
title_sort evaluation of adherence to oral hypoglycemic agent prescription in patients with type 2 diabetes
topic Original Data
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380091/
https://www.ncbi.nlm.nih.gov/pubmed/33905472
http://dx.doi.org/10.1900/RDS.2020.16.41
work_keys_str_mv AT iranimahtab evaluationofadherencetooralhypoglycemicagentprescriptioninpatientswithtype2diabetes
AT yazdimohammadsarafraz evaluationofadherencetooralhypoglycemicagentprescriptioninpatientswithtype2diabetes
AT iranimeisam evaluationofadherencetooralhypoglycemicagentprescriptioninpatientswithtype2diabetes
AT sistanisinanaghibi evaluationofadherencetooralhypoglycemicagentprescriptioninpatientswithtype2diabetes
AT gharehsahar evaluationofadherencetooralhypoglycemicagentprescriptioninpatientswithtype2diabetes